[go: up one dir, main page]

MX2009006526A - Metodo para suministrar terapia con pirfenidona a un paciente. - Google Patents

Metodo para suministrar terapia con pirfenidona a un paciente.

Info

Publication number
MX2009006526A
MX2009006526A MX2009006526A MX2009006526A MX2009006526A MX 2009006526 A MX2009006526 A MX 2009006526A MX 2009006526 A MX2009006526 A MX 2009006526A MX 2009006526 A MX2009006526 A MX 2009006526A MX 2009006526 A MX2009006526 A MX 2009006526A
Authority
MX
Mexico
Prior art keywords
patient
pirfenidone therapy
pirfenidone
discloses
adverse events
Prior art date
Application number
MX2009006526A
Other languages
English (en)
Inventor
Williamson Ziegler Bradford
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39259551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009006526(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of MX2009006526A publication Critical patent/MX2009006526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/50—General identification or selection means using icons or symbolic figures, e.g. by a graphical representation symbolising the type of pathology or the organ by an image

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se relaciona con los métodos para disminuir los eventos adversos asociados con la terapia con la pirfenidona [5-metil-1-fenil-l-(1H)-piridona]. La invención revela un esquema de escalamiento de dosis optimizado que resulta en el incremento de la tolerancia del paciente hacia los eventos adversos asociados con la administración de pirfenidona. La invención también revela un paquete inicial que puede ser utilizado en conjunción con el esquema de escalamiento de la dosis.
MX2009006526A 2006-12-18 2007-12-18 Metodo para suministrar terapia con pirfenidona a un paciente. MX2009006526A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87059306P 2006-12-18 2006-12-18
PCT/US2007/087988 WO2008077068A1 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient

Publications (1)

Publication Number Publication Date
MX2009006526A true MX2009006526A (es) 2009-06-30

Family

ID=39259551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006526A MX2009006526A (es) 2006-12-18 2007-12-18 Metodo para suministrar terapia con pirfenidona a un paciente.

Country Status (14)

Country Link
US (9) US7767700B2 (es)
EP (4) EP3053580B1 (es)
JP (1) JP2010513320A (es)
AT (1) ATE506060T1 (es)
CA (1) CA2667654C (es)
CY (1) CY1111699T1 (es)
DE (1) DE602007014113D1 (es)
DK (1) DK2124945T3 (es)
ES (3) ES2581844T3 (es)
MX (1) MX2009006526A (es)
PL (2) PL2124945T3 (es)
PT (1) PT2124945E (es)
SI (1) SI2124945T1 (es)
WO (1) WO2008077068A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE506060T1 (de) 2006-12-18 2011-05-15 Intermune Inc Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten
AU2012205256B2 (en) * 2008-11-10 2015-05-28 Intermune, Inc. Pirfenidone Treatment for Patients with Atypical Liver Function
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
SG172981A1 (en) * 2009-01-26 2011-08-29 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US10092552B2 (en) 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
US9682071B2 (en) 2013-03-15 2017-06-20 Intermune, Inc. Methods of improving microvascular integrity
USD731783S1 (en) 2014-04-16 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD731171S1 (en) 2013-10-07 2015-06-09 Abbvie Inc. Template for a prescription medicine container
USD731782S1 (en) 2013-10-07 2015-06-16 Abbvie Inc. Template for a prescription medicine container
EP3091976B1 (en) 2014-01-10 2024-07-24 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2017165497A1 (en) * 2016-03-22 2017-09-28 Leof Edward B Using fatty acid synthase inhibitors to treat fibrosis
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3108048A1 (en) 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
USD930974S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
US11052021B2 (en) 2018-03-22 2021-07-06 Abbvie Inc. Medicine container, method of assembling the container, and method of dispensing the medicine from the container
USD930973S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
USD882243S1 (en) 2018-03-26 2020-04-28 Abbvie Inc. Child-resistant medication container assembly
EP3829632A4 (en) * 2018-07-27 2022-05-04 Société des Produits Nestlé S.A. SYSTEMS AND METHODS FOR DELIVERING UNIT DOSES OF ORAL IMMUNOTHERAPY
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
GB2589635B (en) * 2019-12-06 2021-12-01 Merxin Ltd Elongate form medicament carrier and medicament dispenser
WO2022194941A1 (en) * 2021-03-17 2022-09-22 Actelion Pharmaceuticals Ltd Pharmaceutical dosage system
CN119630395A (zh) 2022-02-28 2025-03-14 努福米克斯技术有限公司 用于治疗特发性肺纤维化的组合物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US695044A (en) * 1901-12-28 1902-03-11 Albert E Gibson Non-refillable bottle.
SE9502370D0 (sv) 1995-06-30 1995-06-30 Astra Ab Blister pack, especially for drugs, as well as method and device in manufacturing the same
US6956044B1 (en) * 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
EP1356816B1 (en) * 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
CA2496577A1 (en) * 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
CN101039957A (zh) * 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US20070053877A1 (en) * 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
GEP20105124B (en) * 2005-07-25 2010-11-25 Array Biopharma Inc Novel macrocyclic inhibitors of hepatitis c virus replication
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US20080003635A1 (en) * 2006-06-12 2008-01-03 Intermune, Inc. High Throughput Collagen Synthesis Assay
ATE533486T1 (de) * 2006-06-15 2011-12-15 Shanghai Genomics Inc Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
ATE506060T1 (de) 2006-12-18 2011-05-15 Intermune Inc Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders

Also Published As

Publication number Publication date
SI2124945T1 (sl) 2011-08-31
HK1133584A1 (en) 2010-04-01
US20200113884A1 (en) 2020-04-16
US8420674B2 (en) 2013-04-16
EP2471534A1 (en) 2012-07-04
PL3053580T3 (pl) 2021-12-20
HK1153647A1 (en) 2012-04-05
CY1111699T1 (el) 2015-10-07
EP3053580A1 (en) 2016-08-10
US20090197923A1 (en) 2009-08-06
CA2667654C (en) 2016-12-13
WO2008077068A1 (en) 2008-06-26
US20080194644A1 (en) 2008-08-14
DE602007014113D1 (de) 2011-06-01
EP2338489B1 (en) 2016-04-27
PL2124945T3 (pl) 2011-09-30
JP2010513320A (ja) 2010-04-30
EP2124945B1 (en) 2011-04-20
ES2581844T3 (es) 2016-09-07
US20160324842A1 (en) 2016-11-10
US20100324097A1 (en) 2010-12-23
PT2124945E (pt) 2011-07-01
US20190000821A1 (en) 2019-01-03
CA2667654A1 (en) 2008-06-26
DK2124945T3 (da) 2011-08-01
ATE506060T1 (de) 2011-05-15
US20130220871A1 (en) 2013-08-29
EP3053580B1 (en) 2021-06-30
ES2395396T3 (es) 2013-02-12
US7767700B2 (en) 2010-08-03
US20190247380A1 (en) 2019-08-15
US7696236B2 (en) 2010-04-13
EP2338489A1 (en) 2011-06-29
US20180140588A1 (en) 2018-05-24
ES2882956T3 (es) 2021-12-03
EP2124945A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
MX2009006526A (es) Metodo para suministrar terapia con pirfenidona a un paciente.
WO2008144241A3 (en) Altering pharmacokinetics of pirfenidone therapy
PH12015500719A1 (en) Gdf-8-inhibitors
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
EP4592275A3 (en) Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
PH12014500386A1 (en) Combination treatment for hepatitis c
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2010002736A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
PH12014500381A1 (en) Therapeutic methods
WO2011131370A8 (en) Melt-granulated fingolimod
WO2012002773A3 (en) Phenylcarbamate compound and muscle relaxant containing the same
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
GB201022049D0 (en) Methods
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
WO2008019136A3 (en) Transdermal atomoxetine formulations and associated methods
WO2011156900A3 (en) Compounds, compositions and methods for treatment of multiple sclerosis
MX2010007607A (es) (e)-n-{3-[1-(8-fluoro-11h-10-oxa-1-aza-dibenzo [a,d] ciclohepten-5iliden)-propil}-fenil}-metilsulfon amida como modulador de receptor glucocorticoide para el tratamiento de reumatoide.
UA54146U (ru) Способ профилактики воспалительных осложнений и болевого синдрома при удалении зубов
UA48564U (ru) Способ лечения больных остеоартрозом
UA34819U (ru) Способ лечения больных неалкогольным стеатогепатитом

Legal Events

Date Code Title Description
FG Grant or registration